Rose bengal sodium - Provectus Biopharmaceuticals
Alternative Names: PH-10; Provecta; PV-10; Rose bengal; Rose bengal disodium; Rose bengal sodium I 125; Rose bengal sodium I 131; XantrylLatest Information Update: 28 May 2024
At a glance
- Originator Photogen Technologies Inc.
- Developer Pediatric Oncology Experimental Therapeutics Investigators Consortium; Provectus Biopharmaceuticals; University of Calgary
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antibacterials; Antineoplastics; Antipsoriatics; Antivirals; Benzoates; Eye disorder therapies; Fluoresceins; Halogenated hydrocarbons; Skin disorder therapies; Small molecules; Xanthenes
- Mechanism of Action Cell death stimulants; Cell membrane modulators; Dendritic cell stimulants; Immunostimulants; Interferon modulators; Interleukin 17 modulators; Interleukin-22 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Malignant melanoma
- Phase II Atopic dermatitis; Psoriasis
- Phase I Actinic keratosis; Neuroendocrine tumours
- Preclinical COVID 2019 infections; Ewing's sarcoma; Gram-negative infections; Gram-positive infections; Haematological malignancies; Infectious keratitis; Lymphoid leukaemia; Myeloid leukaemia; Osteosarcoma; Rhabdomyosarcoma; Solid tumours; Squamous cell cancer; Wounds
- No development reported Liver cancer; Liver metastases; Pancreatic cancer
- Discontinued Acne vulgaris; Breast cancer